Assessment of outcomes and biomarkers in colorectal cancer
Official title: Prospective, Population-based Cohort Collection of Blood Samples and Tumor Tissue From Patients Operated on for Primary or Metastatic Colorectal Cancer
Run by Helse Stavanger HF · NCT01762813 · Data updated 2026-11-12
This study is trying to see how well surgery works for people with colorectal cancer and if certain blood and tissue markers can help predict their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1200 (estimated) |
| Sponsor | Helse Stavanger HF Government |
| Locations | 1 site (Stavanger) |
| Status | Recruiting |
| Started | January 1, 2013 |
| Main results expected | December 31, 2035 |
| Study ends | December 31, 2036 |
| Registry record updated | April 30, 2026 |
| Trial ID | NCT01762813 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with primary or metastatic colorectal cancer who are planning to undergo curative surgery.
✕Probably not a fit
Patients who are unable to provide informed consent or those not planning to undergo surgical treatment for their colorectal cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on the clinical outcomes of surgical management for patients with primary and metastatic colorectal cancer. It involves the prospective collection of tissue samples to explore potential biomarkers in blood and tumor tissues. The study aims to assess clinical outcomes through molecular profiling and patient-reported outcomes, providing insights into the effectiveness of surgical interventions. Data will be gathered to understand the relationship between clinical pathways and patient results.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of colorectal cancer management and improve patient outcomes through personalized treatment approaches.
How similar studies have gone: Other studies have shown promise in using biomarker analysis for colorectal cancer, indicating that this approach has potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of colorectal cancer, primary or metastatic (liver), with a treatment intention of planned curative surgery * Informed consent to participate * Age ≥18 Exclusion Criteria: * failure to provide written informed consent
Where it's running
-
Stavanger University Hospital
Stavanger, Norway Recruiting
Study contacts
- Principal investigator: Kjetil Søreide, MD, PhD, FRCS, FACS — Helse Stavanger HF
- Study coordinator: Ramesh L. Kajavi, RN
- Email: acro.gitan@gmail.com
- Phone: 92297672
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.